---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-026269"
form_type: "8-K"
ticker: "BIXT"
cik: "0001445815"
company_name: "BIOXYTRAN, INC"
filed_at: "2024-07-05T23:59:59+00:00"
generated_at: "2026-05-31T23:19:48.368405+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "medium"
source: SEC EDGAR
---

# Bioxytran announces Springer book linking hyperbaric oxygenation to BXT-25 drug

## Summary
- Book by Prof. Mayevsky published by Springer; covers hyperbaric oxygenation and mitochondrial activity.
- BXT-25 is an acellular oxygen carrier (AOC) 5,000x smaller than RBC; aims to replace HBOT.
- MDX Viewer (FDA-approved) measures tissue oxygenation via Brain Metabolic Score (BMS).
- BMS used as biomarker to demonstrate efficacy in upcoming stroke and Alzheimer's trials.
- Company expects coupling BXT-25 with MDX Viewer could shorten clinical trial timelines.

## SEC filing metadata
- accession: 0001493152-24-026269
- form_type: 8-K
- ticker: BIXT
- cik: 0001445815
- company_name: BIOXYTRAN, INC
- filed_at: 2024-07-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1445815/000149315224026269/0001493152-24-026269-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1445815/000149315224026269/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-026269
- JSON: https://secwatch.observer/filing/0001493152-24-026269.json
- Plain text: https://secwatch.observer/filing/0001493152-24-026269.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.